< Back to latest news & events

Event

IP in Healthcare Conference 2020

March 2020

Event date: 3rd March 2020

March 2020 in London and Manchester. HGF’s sixth annual Healthcare Conference reviews the latest intellectual property issues in the pharmaceuticals, life sciences and medical devices sectors.

Update

It is with great regret that we have taken the decision to cancel the HGF IP in Healthcare conference in London on Thursday 12th March. This is a precautionary measure by the firm based on current situation surrounding the Coronavirus in the UK and Europe.

We would like to take this opportunity to thank you for reserving your place and we look forward to welcoming you again in 2021.

Dates

The Conference will take place on the following dates:

  • Tuesday 3rd March in Alderley Park, Manchester
  • Thursday 12th March in Barber-Surgeons Hall, London *Cancelled*
About HGF Healthcare team

HGF’s Healthcare team provides professional expertise and commercially focused advice to business leaders and decision makers in the healthcare fields of life sciences, pharmaceuticals and medical devices. HGF has in-depth knowledge of the sector, and the experience to provide you with high quality and commercially focused advice in relation to the protection of your IP rights. The team offers the full range of IP services including:

  • IP strategy and advice;
  • Patent and trade mark procurement;
  • IP portfolio management;
  • Freedom-to-operate advice and opinions;
  • IP due diligence assessments and opinions;
  • Supplementary protection certificates and data exclusivity advice;
  • IP licences and agreements;
  • IP disputes management and litigation

For more information on the team please click here.

Please join our Healthcare+IP LinkedIn group which discusses stories and legal developments in the intellectual property field which impacts the healthcare sector.

Latest updates

Wrestling with G1/24 – How should the claims be interpreted in view of the description?

In G1/24, the Enlarged Board of Appeal (EBA) codified how claims should be interpreted for assessing patentability: in consultation with the description. However, the decision was light on how, in …

Read article

Welcome to HGF Presents - New Video Series

Introducing HGF Presents a new video series delivering practical insights into European Patent Law and practice. Curated by our leading experts in chemistry, life sciences, technology & engineering, each concise …

Read article

Seminar on Incorporating Trade Secrets into your IP Strategy

HGF is hosting a Seminar on Incorporating Trade Secrets into your IP Strategy which will be followed by networking, apero, and snacks. The Seminar will be held on Wednesday, 10th …

Read article

PRESS RELEASE – HGF strengthens European presence with three new Partners in France and Germany

HGF is pleased to announce the arrival of three new partners, further strengthening its European presence. Two partners will be joining the firm’s fast-growing French practice, and one will join …

Read article

Providing Enabling Disclosure for AI inventions at the EPO

  Video overview: The equivalent to the enablement requirement in the US at the EPO is Sufficiency. There is an increasing trend for the sufficiency of AI related patent applications …

Read article

Personalised Medicine Patenting of Known Drugs for Known Indications at the EPO

Video overview: The identification of specific sub-groups of patients to treat with a known drug, even if said patients may have been treated before with the drug, can yield patentable …

Read article

Novelty Over Clinical Trials at the EPO

Video overview: Second medical use claims can be novel over clinical trials in European patents. Typically, such a claim would be fairly narrow, e.g. perhaps mapping onto specific indications and …

Read article

Regulatory Exclusivity for
Medicinal Products in Europe

Video overview: New Medical Products 8 years of data exclusivity, followed by 2 years of market exclusivity. +1 year market exclusivity possible for a new indication showing significant clinical benefit. No exclusivity granted for new formulations or routes of …

Read article